B Kocer, B Nazliel, M Oztas, H Z Batur. Show Affiliations »
Abstract
Entities: Disease Species
Mesh: See more » Adjuvants, Immunologic/adverse effectsAdjuvants, Immunologic/therapeutic useAdultFemaleHumansInterferon Type I/administration & dosageInterferon Type I/adverse effectsInterferon Type I/therapeutic useInterferon beta-1aInterferon-beta/administration & dosageInterferon-beta/adverse effectsInterferon-beta/therapeutic useMultiple Sclerosis/drug therapyRecombinant ProteinsSkin Pigmentation/drug effectsVitiligo/chemically induced
Substances: See more » Adjuvants, ImmunologicInterferon Type IRecombinant ProteinsInterferon-betaInterferon beta-1a
Year: 2009 PMID: 19222549 DOI: 10.1111/j.1468-1331.2009.02563.x
Source DB: PubMed Journal: Eur J Neurol ISSN: 1351-5101 Impact factor: 6.089